BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19483700)

  • 1. Tapping into combination pills for HIV.
    Hughes B
    Nat Rev Drug Discov; 2009 Jun; 8(6):439-40. PubMed ID: 19483700
    [No Abstract]   [Full Text] [Related]  

  • 2. Gilead AIDS pill effective in study with weekends off.
    AIDS Read; 2008 Dec; 18(12):593. PubMed ID: 19123271
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA makes final approvals.
    AIDS Patient Care STDS; 2006 May; 20(5):381. PubMed ID: 16758553
    [No Abstract]   [Full Text] [Related]  

  • 4. Minor emtricitabine intolerance in treatment-stable patients switched from tenofovir/lamivudine to a fixed-dose combination of tenofovir/emtricitabine (Truvada).
    Palacios R; Terrón A; Hidalgo A; Rivero A; Santos J;
    J Antimicrob Chemother; 2008 Feb; 61(2):462-3. PubMed ID: 18156608
    [No Abstract]   [Full Text] [Related]  

  • 5. Findings in humanized-mouse model suggest benefit of further studies in HIV pre-exposure prophylaxis.
    Expert Rev Clin Immunol; 2010 Mar; 6(2):186. PubMed ID: 20402380
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
    Redfield RR; Morrow JS
    Clin Infect Dis; 2008 Oct; 47(7):984-5. PubMed ID: 18778234
    [No Abstract]   [Full Text] [Related]  

  • 7. [First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():12-4. PubMed ID: 19024908
    [No Abstract]   [Full Text] [Related]  

  • 8. The art of managing human immunodeficiency virus infection: a balancing act.
    Reiss P
    Clin Infect Dis; 2009 Nov; 49(10):1602-4. PubMed ID: 19842978
    [No Abstract]   [Full Text] [Related]  

  • 9. [HIV therapy: tenofir DF is available in 68 developing countries at production costs price].
    Med Klin (Munich); 2003 Jul; 98(7):XV-XVI. PubMed ID: 12945544
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial comment: HIV and HBV coinfection--a coming-of-age in treatment strategies.
    Ala A; Dieterich DT
    AIDS Read; 2004 Mar; 14(3):134-5. PubMed ID: 15068001
    [No Abstract]   [Full Text] [Related]  

  • 11. A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate.
    De Clercq E
    Expert Opin Pharmacother; 2009 Dec; 10(17):2935-7. PubMed ID: 19929712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Simply convincing. New fixed combination for HIV therapy].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():20-3. PubMed ID: 16385865
    [No Abstract]   [Full Text] [Related]  

  • 13. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
    Nüesch R; Ananworanich J; Srasuebkul P; Chetchotisakd P; Prasithsirikul W; Klinbuayam W; Mahanontharit A; Jupimai T; Ruxrungtham K; Hirschel B
    AIDS; 2008 Jan; 22(1):152-4. PubMed ID: 18090405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BMS issues PK notice regarding ATV + TDF.
    IAPAC Mon; 2003 Sep; 9(9):203. PubMed ID: 14672069
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA notifications. Updated Atripla label approved.
    AIDS Alert; 2010 Mar; 25(3):36. PubMed ID: 20629262
    [No Abstract]   [Full Text] [Related]  

  • 16. European CHMP issues positive opinion for Atripla.
    AIDS Patient Care STDS; 2007 Nov; 21(11):890. PubMed ID: 18338431
    [No Abstract]   [Full Text] [Related]  

  • 17. The introduction of new antiretroviral-based HIV prevention methods into health systems: an update.
    Daly F
    Reprod Health Matters; 2012 Jun; 20(39):215. PubMed ID: 22789099
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
    Lapadula G; Costarelli S; Quiros-Roldan E; Calabresi A; Izzo I; Carosi G; Torti C
    Clin Infect Dis; 2008 Apr; 46(7):1127-9. PubMed ID: 18444839
    [No Abstract]   [Full Text] [Related]  

  • 19. 96-week CASTLE data show similar efficacy results.
    AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention. Using PrEP cost-effective in high-risk MSM groups.
    AIDS Policy Law; 2012 Jun; 27(7):1. PubMed ID: 22803211
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.